REGISTRATION IS NOW OPEN!
Building on two successful years in Paris (2015) and London (2016), we are happy to announce that registration for the Molecular Analysis for Personalised therapy (MAP) conference 2017 is now open.
On October 13 – 14 we will be in Zurich, Switzerland to discuss the clinical interpretation of molecular tests for metastatic cancers, alongside medical oncologists, researchers, onco-geneticians, clinical investigators, molecular biologists, cytopathologists, radiotherapists, fellow, academics, regulators and Industry R&D representatives.
Given the rapid increase in targeted therapies now available, we anticipate attendees and speakers at the third MAP Conference will propel ideas and broker new discussions on how to interpret genomic data in precision medicine.
Over two days, world-renowned medical and health professionals will present findings on various topics related to personalised cancer therapy. These discussions are important to help diminish the major gap between our understanding of cancer biology and our evolving approach to patient management.
Topics for this year include:
• Macroevolution and impact on treatment resistance
• New models and technologies for personalised medicine
• Personalised medicine applied to immunotherapeutics
• Therapeutic targets in cancer
• Treatment advances in central nervous system tumours
• Tumour microenvironment and treatment resistance
• Understanding the broader tumour microenvironment
• What’s new in the field of clinical trials?
A joint initiative of ESMO, UNICANCER and Cancer Research UK, this conference shines a light on the latest medical developments in a constantly evolving field.
The best abstracts submitted for MAP 2017 will be selected to present their findings during the sessions at the conference.
New to MAP 2017: accepted abstracts will be edited in the "Annals of Oncology" journal.
An application has been made to the EACCME® for CME accreditation.
The MAP 2016 edition was accredited 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).
“The MAP conference was a pleasant conference with excellent speakers. Its interactive nature allowed a very interesting share of knowledge and a refreshing update about the current investigations in personalised medicine and their interaction with the clinical practice. It was a privilege to take part in this conference and I would absolutely recommend it to my colleagues.”
Ana Sofia Patrão, Interna de Formação Especifica Oncologia Médica - Instituto Português de Oncologia, Porto
“MAP 2015 was a great conference providing a succinct overview of a number of the important topics in precision medicine. It was also a great networking event to meet with colleagues and discuss potential future projects.”
Dr Crispin Hiley - The Francis Crick Institute, London
“I came to MAP this year to talk about the impact of precision cancer medicine and the huge improvements in molecular diagnostics and therapeutics on society, particularly, how we’re going to make things in the future affordable and sustainable. It’s been a lot of fun, very engaging in conversation and I thoroughly recommend this conference to people in the future.”
Richard Sullivan, Professor of Cancer and Global Health – Kings College, London
“This conference is exceptional because it truly unites the key players in the field of precision medicine. It also permits us to see where we are heading and how to take into consideration the issues facing research, the financial and economic issues and above all how the patients could be involved in these choices. I believe that we’re tackling the future of cancerology in its most modern and promising aspects.”
Fabien Calvo, Chief Scientific Officer, Cancer Core European Director - Cancer Care Europe, Villejuif